InterMune PT Raised to $74.00 (ITMN)
William Blair hoisted their price target on shares of InterMune (NASDAQ:ITMN) from $55.00 to $74.00 in a research note issued on Monday. William Blair’s price objective indicates a potential upside of 37.55% from the company’s current price.
Several other analysts have also recently commented on the stock. Analysts at Stifel Nicolaus downgraded shares of InterMune from a “buy” rating to a “hold” rating in a research note on Monday. Separately, analysts at Leerink Swann raised their price target on shares of InterMune from $53.00 to $74.00 in a research note on Monday. Finally, analysts at Robert W. Baird raised their price target on shares of InterMune from $50.00 to $74.00 in a research note on Monday. They now have an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the stock. InterMune presently has a consensus rating of “Hold” and a consensus price target of $51.55.
In other InterMune news, EVP Paul D. Arata sold 7,500 shares of the stock on the open market in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $50.00, for a total value of $375,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
InterMune (NASDAQ:ITMN) opened at 53.80 on Monday. InterMune has a 52 week low of $10.95 and a 52 week high of $55.24. The stock’s 50-day moving average is $45.86 and its 200-day moving average is $36.13. The company’s market cap is $5.809 billion.
InterMune (NASDAQ:ITMN) last released its earnings data on Wednesday, August 6th. The company reported ($0.72) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter last year, the company posted ($0.77) earnings per share. InterMune’s revenue was up 141.2% compared to the same quarter last year. Analysts expect that InterMune will post $-2.75 earnings per share for the current fiscal year.
InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.